Novartis AG is partnering with Lindy Biosciences to make biologics normally available only as intravenous injections suitable for subcutaneous self-administration, which the companies said would improve outcomes as well as compliance among patients. For Novartis, it shows the company is interested in making its biologics – especially monoclonal antibodies – easier for patients to use, but is also taking a different tack from other pharma companies that have created subcutaneous versions of their products.
Honey, I Shrunk The Drugs: Novartis, Lindy Partner On Biologics Delivery
Novartis is paying Lindy potentially more than $900m to use its technology for making intravenous biologics available for subcutaneous injection using autoinjectors.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
More from Business
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.